CYCC and SNSS do not compete. CYCC is going after the much larger first line market opportunity. In contrast, SNSS is going after relapsed second line cases. In addition, SNSS are using a protocol of Voreloxin with toxic Chemo and is not being submitted as a single agent. Bottom line, SNSS can't shine CYCC's shoes.